LYVE1 and lymphedema: ,13,14 Here, using a surgical mouse model of secondary lymphedema, we demonstrated that targeting IGF1R signaling with linsitinib restricted both tissue swelling and pathological remodeling of LYVE-1+ lymphatics (i.e., initial and/or precollector lymphatics) during lymphedema development.